Preclinical studies of ZG19018, a novel irreversible covalent inhibitor of KRAS G12C, for the treatment of advanced nonsmall cell lung cancer and other solid tumors

被引：0
|
作者：
Zhu, Bing
Cui, Dawei
Liu, Ruifeng
Feng, Weidong
Sheng, Zelin
Lv, Binhua
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2790
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2790
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).
    Fakih, Marwan
    Durm, Greg Andrew
    Govindan, Ramaswamy
    Falchook, Gerald Steven
    Soman, Neelesh
    Henary, Haby Adel
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
    Lugowska, Iwona A.
    Rojas, Carlos
    Stathis, Anastasios
    Weindler, Susanne
    Pal, Abhijit
    Alvarez, Eduardo Castanon
    Mackiewicz, Jacek
    Garrido, Marcelo
    Sendur, Mehmet Ali Nahit
    Lakhani, Nehal J.
    Frentzas, Sophia
    Dziadziuszko, Rafal
    Sacher, Adrian G.
    Wakuda, Kazushige
    Kato, Terufumi
    Perets, Ruth
    Castillo Fernandez, Omar Orlando
    Jemielita, Thomas
    Choi, Yewon
    Juergens, Rosalyn A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS232 - TPS232
  • [43] Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy
    Justeau, Gregoire
    Huchot, Eric
    Simonneau, Yannick
    Roa, Magali
    Le Treut, Jacques
    Le Garff, Gwenaelle
    Bylicki, Olivier
    Schott, Roland
    Bravard, Anne-Sophie
    Tiercin, Marie
    Lamy, Regine
    De Chabot, Gonzague
    Marty, Adina
    Moreau, Diane
    Locher, Chrystele
    Bernier, Cyril
    Chouaid, Christos
    Descourt, Renaud
    LUNG CANCER, 2022, 174 : 45 - 49
  • [44] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non-Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
    Janne, P. A.
    Rybkin, I. I.
    Spira, A. I.
    Riely, G. J.
    Papadopoulos, K. P.
    Sabari, J. K.
    Johnson, M. L.
    Heist, R. S.
    Bazhenova, L.
    Barve, M.
    Pacheco, J. M.
    Leal, T. A.
    Velastegui, K.
    Cornelius, C.
    Olson, P.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Ou, S. H. I.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S1 - S2
  • [45] Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
    Dong, Xiaorong
    Meng, Xiangjiao
    Zhang, Yan
    Wang, Yan
    Chen, Jianhua
    Han, Liang
    Wang, Qiming
    Lin, Zhong
    Wei, Hongying
    Lin, Siheng
    Li, Chuan
    Wu, Qiong
    CANCER RESEARCH, 2024, 84 (07)
  • [46] A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)
    Hong, David S.
    Yaeger, Rona
    Kuboki, Yasutoshi
    Masuishi, Toshiki
    Barve, Minal A.
    Falchook, Gerald Steven
    Govindan, Ramaswamy
    Sohal, Davendra
    Kasi, Pashtoon Murtaza
    Burns, Timothy F.
    Langer, Corey J.
    Puri, Sonam
    Chan, Emily
    Jafarinasabian, Pegah
    Ngarmchamnanrith, Gataree
    Rehn, Marko
    Tran, Qui
    Gandara, David R.
    Strickler, John H.
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
    Hong, David S.
    Kuo, James
    Sacher, Adrian G.
    Barlesi, Fabrice
    Besse, Benjamin
    Kuboki, Yasutoshi
    Dy, Grace K.
    Dembla, Vikas
    Krauss, John C.
    Burns, Timothy F.
    Kim, June
    Henary, Haby
    Ngarmchamnanrith, Gataree
    Li, Bob T.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Fiala, Ondrej
    Pesek, Milos
    Finek, Jindrich
    Benesova, Lucie
    Belsanova, Barbora
    Minarik, Marek
    CANCER GENETICS, 2013, 206 (1-2) : 26 - 31
  • [49] Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
    Julian, Cristina
    Pal, Navdeep
    Gershon, Anda
    Evangelista, Marie
    Purkey, Hans
    Lambert, Peter
    Shi, Zhen
    Zhang, Qing
    BMC CANCER, 2023, 23 (01)
  • [50] Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis
    Erhart, Caroline-Claudia
    Cefali, Marco
    Mangan, Dylan
    Kasenda, Benjamin
    Wannesson, Luciano
    SWISS MEDICAL WEEKLY, 2024, 154
12345